Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has been downgraded to Strong Sell in a statement by Zacks Investment Research earlier today.
- Updated: September 27, 2016
Zacks Investment Research has downgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to Strong Sell in a statement released on Tuesday September 27, 2016.
On 09/15/2016, Stifel Nicolaus released a statement for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) bumped up the target price from $105.00 to $109.00 that suggested an upside of 0.21%.
Boasting a price of $88.18, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded -0.84% lower on the day. With the last stock price close down -2.34% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Vertex Pharmaceuticals Incorporated has recorded a 50-day average of $96.39 and a two hundred day average of $89.65. Volume of trade was down over the average, with 486,374 shares of VRTX changing hands under the typical 1,341,270
With a total market value of $0, Vertex Pharmaceuticals Incorporated has with a one year low of $75.90 and a one year high of $134.71 .
A total of 20 equity analysts have released a ratings update on VRTX. Eight equity analysts rating the company a strong buy, ten equity analysts rating the company a buy, seven equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $110.30.
General Company Details For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Its marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. It is engaged in various other research and mid- and early-stage development programs, such as programs in the areas of oncology, pain and neurology. Its oncology drug candidates include VX-970, VX-803 and VX-984; pain drug candidates include VX-150 and VX-241, and acute spinal cord injury drug candidate include VX-210.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.